NYS Bar Non-Consensual Research
Please click here for a presentation on Non-Consensual Research
Please click here for a presentation on Non-Consensual Research
The efficacy and safety of a new drug that treats a serious and life threatening illness in premature infants will be studied versus sham/placebo in Latin America. The sponsor plans to apply for FDA approval, in addition to local and European registration. There are approved therapies (surfactants) for this illness (Respiratory Distress Syndrome, or RDS) in those countries where this trial is proposed to take place, and surfactants are even used in some of their hospitals. However, surfactants are completely unavailable to infants at many other hospitals, secondary to rationing or economic limitations.
FDA Considers: Use of Placebo-Controls in Life Threatening Diseases: Is the Developing World the Answer? The efficacy and safety of a new drug that treats a serious and life threatening illness in premature infants will be studied versus sham / placebo in Latin America.
"Every fifth-grader and ninth grader" is targeted form mental screening in Syracuse, NY.
Dr. Karen Effrem refutes Dr Friedman who claims there is "a silent epidemic of mental illness among teenagers."
When scientists are for sale and "peer reviewed" journals publish planted commercial pronouncements masquerading as "science" news reports, the public is advised to disregard those "news" reports and wait for the evidence to be independently examined and either corroborated or refuted.
A scientifically invalid study by financially compromised psychiatrists is but industy’s latest effort to rehabilitate SSRI antidepressants in the wake of public disclosure that these drugs DOUBLED the risk of suicidal acts.
The chemical abuse of U.S. children in foster care represent the collapse of civilized medicine.
These paid lobbying efforts on behalf of industry are carried out under the pretext of advocacy in the public interest.
Minnesota is the first of a handful of states to pass a law requiring drug manufacturers to disclose payments to doctors.
The re-prioritization of rapid approvals occurred at the expense of drug safety standards,
A First Amendment lawyer challenges the rationale given by Judge Jack Weinstein for sealing the Zyprexa documents in the first place.